EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD

Ishfaq Rashid, Hiddo J L Heerspink, Lesley A Inker

American Journal of Kidney Diseases · 2026-11

DOI: 10.1053/j.ajkd.2026.06.033 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Kidney Diseases, 2026-11. Verfasst von Ishfaq Rashid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Tufts Medical Center, Boston, MA, USA. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a global public health challenge, yet therapeutic evaluation and regulatory acceptance are constrained by reliance on late clinical endpoints such as kidney failure. Albuminuria, assessed as urine albumin-to-creatinine ratio (UACR) reflects glomerular and systemic vascular injury and responds rapidly to treatment. Epidemiologic evidence demonstrates a continuous, graded association between both baseline and changes in UACR and subsequent risk for kidney failure, cardiovascular events, and mortality. Trial level analyses demonstrate that treatment effects on change in UACR is also associated with long-term treatment benefit on CKD progression across drug classes and disease populations. Meta-analysis indicates that a treatment benefit of ≥30% decline in UACR is associated with approximately a 20% treatment benefit on CKD progression, supporting its use as a clinically meaningful surrogate endpoint. Residual albuminuria during treatment identifies patients at persistently high risk and provides a rationale for therapy intensification. Recent studies demonstrate that combination therapies can achieve substantial additional reductions in UACR, in selected settings exceeding 50%. This review synthesizes biological, epidemiologic, and clinical trial evidence supporting albuminuria-guided risk stratification and a treat-to-target approach using serial UACR monitoring to personalize CKD care, while improving clinician understanding of albuminuria changes as markers of therapeutic response.

Schlagwörter

Stichwörter der Autor:innen

CKDUrine albumin-to-creatinine ratioalbuminuriabiomarkerschronic kidney diseaserisk stratificationtherapeutic response

Autor:innen und Institutionen

  • Division of Nephrology, Tufts Medical Center, Boston, MA, USA.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Division of Nephrology, Tufts Medical Center, Boston, MA, USA. Electronic address: lesley.inker@tuftsmedicine.org.

Zitieren

APA

Rashid, I., Heerspink, H. J. L., & Inker, L. A. (2026). An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2026.06.033

Vancouver

Rashid I, Heerspink HJL, Inker LA. An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD. American Journal of Kidney Diseases. 2026. doi:10.1053/j.ajkd.2026.06.033

BibTeX
@article{Rashid2026,
  author = {Rashid, Ishfaq and Heerspink, Hiddo J L and Inker, Lesley A},
  title = {An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD},
  journal = {American Journal of Kidney Diseases},
  year = {2026},
  doi = {10.1053/j.ajkd.2026.06.033}
}
Kostenlos starten →